340B Dispute Resolution Decisions Subject To Administrative Appeal Under Proposal
US Health and Human Services Department revises approach to 340B administrative dispute resolution process and presiding panel in proposed rule.
You may also be interested in...
Manufacturer restrictions on discounts to contract pharmacies may have depressed sales for 340B-discounted diabetes drugs in 2021. But sales in other categories, including oncology, immunology and arthritis drugs, were up by 20% to 40%.
The decision doesn’t directly impact manufacturers or the 340B discounts they are required to provide – and does not address the potentially much broader regulatory issue of whether the Supreme Court’s so-called Chevron doctrine should be changed.
Drug manufacturer actions against contract pharmacies require immediate attention, provider suit says, though HHS’ 340B dispute resolution process ‘holds promise.’